Multimodal profiling unveils a reversible breast basal-like cell state in AKT-inhibitor resistant tumours
Colin D.H. RatcliffeiD, Hugh SparksiD, Giulia L. M. BoezioiD, Yuriy Alexandrov, Robert P. JenkinsiD, Alix Le MaroisiD, Pablo Soro-BarrioiD, Fatemeh Ahdmadi MoughariiD, Heather HulmeiD, Rebecca J. LeeiD, Stephanie StrohbueckeriD, Sudeep JoshiiD, James K. EllisiD, Giacomo FabriniiD, Lucy FlintiD, Anne-Marie FortieriD, Nils GustafssoniD, Ana C. CunhaiD, Louis TullyiD, Morag ParkiD, Fabian FröhlichiD, James I. MacRaeiD, Rachael NatrajaniD, Andrea SerioiD, James BriscoeiD, , Erik A. SahaiiD
Abstract
The PI3K/AKT/mTOR pathway is central to cell metabolism and growth. However, pharmacological inhibition of the pathway is not uniformly effective across cancer types, or even within a single cancer model. In this study, we leverage oblique plane microscopy of triple negative breast cancer organoids, as well as lineage tracing to uncover a source of heterogeneity. Non-genetic resistance to AKT inhibition is associated with basal cell features of normal breast epithelium and the master transcription factor of basal cell state, {Delta}Np63, is sufficient to confer resistance. Cells can transition between states within four weeks and therefore, AKT inhibition only delays tumour growth, with tumours rich in KRT14+ cells resulting. Thus, under selection, triple negative breast cancer exploits a repertoire of cell states inherent to the breast.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 0
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Identification of a shared persistence program in triple-negative breast cancer across treatments and patients
Léa Baudre, Grégoire Jouault, … Céline Vallot·bioRxiv·Mar 17, 2025
- H3K27me3 is a determinant of chemotolerance in triple-negative breast cancer
J. Marsolier, P. Prompsy, … C. Vallot·bioRxiv·Jan 4, 2021
- Contribution of Mesenchymal-like and Epithelial Cellular Subsets to Chemotherapy Resistance in Triple-Negative Breast Cancer
Ngoc Bao Vuong, Olga Y. Korolkova, … Amos M. Sakwe·bioRxiv·Nov 1, 2025
- Combined inhibition of mTOR and PIKKs exploits replicative and checkpoint vulnerabilities to induce death of PI3K-activated triple-negative breast cancer cells
S. S. Chopra, A. Jenney, … P. K. Sorger·bioRxiv·Jul 12, 2019
- Kinome rewiring reveals AURKA is a molecular barrier to the efficacy of PI3K/mTOR-pathway inhibitors in breast cancer
H. J. Donnella, J. T. Webber, … S. Bandyopadhyay·bioRxiv·Jun 30, 2017
- Cholesterol biosynthesis inhibition synergizes with AKT inhibitors in triple-negative breast cancer
Alissandra L. Hillis, Timothy D. Martin, … Alex Toker·Cancer ResearchPeer-reviewed·Jul 18, 2024